IMC Chicago’s Charles River Laboratories CRL Stock Holding History

IMC Chicago’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,293	Closed	-$1.3M	–	6416
2026 Q1	$1.26M	Buy	+7,293	New	+$1.35M	﹤0.01%	3043

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IMC Chicago's CRL Position: Q2 2026 in Review

IMC Chicago sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 7,293 shares — an estimated $1.3M sold.

IMC Chicago first reported a position in CRL in Q1 2026 and held it in 1 quarter. The position peaked at $1.26M in Q1 2026. 436 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

IMC Chicago reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 7,293 Charles River Laboratories shares in Q2 2026, an estimated $1.3M.
IMC Chicago first reported a position in Charles River Laboratories in Q1 2026 and held it in 1 quarter.
IMC Chicago's Charles River Laboratories position peaked at $1.26M in Q1 2026.
436 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.